QIAGEN Inaugurates New Asia Headquarters in Shanghai’s “Biotech Valley”
Expanded facilities to support the company's rapid development in the region
Shanghai, September 8, 2009 - QIAGEN today announced the opening of its new Asia headquarters in Zhangjiang High-Tech Park, Pudong, Shanghai. The announcement was marked by a ceremony hosted by the company's CEO, Mr. Peer M. Schatz, and attended by representatives from industry and public administration. QIAGEN established Shanghai as the location for its Asia headquarters in 2006. Resources and employees that were previously spread across different locations will be brought together at the new site in Zhangjiang High-Tech Park - which has emerged as the biotechnology hub of China.
"Asia is of integral importance to the growth of QIAGEN globally," said Mr. Schatz. "Asia is the fastest growing region within QIAGEN. Even during the global economic slowdown we have significantly expanded our business in the region in both the life science research and molecular diagnostics sectors, posting strong organic growth of 26% and 43% for the first and second quarters of 2009 respectively over the same period in the prior year. I would like to take this opportunity to thank our customers in this region for their support. Also, I am very proud of the accomplishments of our team and our partners and would like to thank them for their contributions to our growth. Our investment in our new headquarters reflects our commitment to fuel this strong growth and puts QIAGEN in the position to further expand its activities in the region."
The new headquarters will also allow the Company to better serve its local customers. Zhangjiang High-Tech Park is home to 15 multinational pharmaceutical R&D centers, 32 Contract Research Organization (CRO) companies, 29 pharma major manufacturing plants and over 200 biotech-pharma companies. QIAGEN's new facility will provide better access to the Company's new technologies and applications and reduce delivery time to thousands of scientists working in the Park. "With a highly competitive platform for all stages of the value chain, Zhangjiang High-Tech Park is an ideal location for QIAGEN's new Asia headquarters," said Mr. Liu Xiaolong, the president of the Zhangjiang Group that manages the Park. "It demonstrates once again that the Zhangjiang High-Tech zone is an excellent business location for leading international life sciences and diagnostic companies. We are pleased to welcome QIAGEN and wish them continued success"
"The new building in the heart of Zhangjiang High-Tech Park marks a new phase of expansion for all of QIAGEN's core business sectors - biomedical research, molecular diagnostics, pharma drug development, and applied testing," said Dr. Victor Shi, Asia President of QIAGEN. "By investing in this new head office we are building the foundation for future growth that will help enhance access to our state-of-the-art sample and assay technologies in Asia."
About QIAGEN Asia:
QIAGEN Asia is the company's fastest growing region. The company began its strategic expansion into the region in 2005 and currently maintains 10 Asian offices located in China, Korea, Malaysia, Singapore and India with over 400 employees. Including the subsidiary in Japan, they currently contribute approximately 13 per cent to QIAGEN's overall net sales. In 2006, QIAGEN received the Frost & Sullivan Award for Competitive Strategy Leadership in recognition of the company's strategic initiatives in the Asia Pacific molecular testing market.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,150 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing and molecular diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.